Kornimate/medical-research-clean huggingface dataset:
action of the vidaza on the atrial fibrillation

Conditions: Atrial Fibrillation; Acute Leukemia

Summary: genomic studies on atrial fibrillation patients have identified polymorphisms in regions surrounding the pitx2 gene, suggesting it could be the locus responsible for atrial fibrillation. the pitx2 gene is essential for establishing the asymmetry between systemic and pulmonary blood flow, which is absolutely required for proper heart functions. in addition, pitx2 is required for the development the atrium myocardium. investigators have performed transcriptomic analysis on left atrium tissues from atrial fibrillation patients and identify genes whose expression is altered in atrial fibrillation. among affected genes, pitx2 expression is strongly decreased in the left atrium of atrial fibrillation patients. moreover, investigators observed that the pitx2 promoter region is hypermethylated in atrial fibrillation patients. interestingly, dna methylation is a key actor of gene expression and directly regulates rna transcription either by directly modulating transcription factor (tf) binding to gene promoters or by modifying local chromatin structures, therefore limiting access of tfs to dna. these epigenetic modifications are reversible and therefore represent an interesting therapeutic target. hence, many compounds that inhibit dna methyl-transferase are currently tested in different disease models. recently-designed hypomethylating molecules are available, such as the 5'azacytidine (vidaza®, celgen inc.) or the 5-aza-2'-deoxycytidine (decitabine) (dacogen®, janssen cilag). investigators have performed preliminary studies on the effect of decitabine on dna methylation and proper cardiac function recovering in a shr model. results indicate that the chronic delivery of decitabine improves the arrhythmia profile by reducing tachyarrhythmia, fibrosis, as well as the oxidative stress in shr left atrium submitted acute leukemia is a rare pathology with an incidence of 4 per 100,000 in france. azacytidine, which is closely related to decitabine, is commonly used for treating acute leukemia and possesses anti-neoplastic effect through multiple mechanisms, including direct cytotoxicity of blood cancer cells and dna hypomethylation. the goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis as well, which are the two mains phenotypic manifestation of atrial fibrillation in humans. investigators hypothesize that azacytidine decreases pitx2 promoter methylation and increases pitx2 expression. hence, investigators expect to ameliorate the duration of atrium action potential and to observe a decrease of atrium fibrosis.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * patient with history of paroxysmal atrial fibrillation, and /or presenting a dilatation of the left atrium. * patient selected for a first vidaza® treatment * non-opposition of the patient to participate in the study exclusion criteria: * age \< 18 years old * no paroxysmal atrial fibrillation * patients with previous history of vidaza® treatment
my health day by day (mi salud dia a dia)

Conditions: Stress, Emotional

Summary: the purpose of this study is to is to evaluate how cognitive behavioral stress management (cbsm) targets (e.g., anxiety reduction, cognitive reappraisal, coping, emotional expression, communication skills, social support) operate through science of behavior change (sobc) measures and influence dyadic adjustment and health related quality of life (hrqol) in prostate cancer (pc) survivors and spouses/partners, in addition to physiologic adaptation and symptom burden in pc survivors.


Eligibility criteria:
inclusion criteria: prostate cancer survivor 1. ≥18 years of age 2. hispanic/latino self- identification 3. spanish speakers (including bilinguals who agree to participate in a spanish intervention) 4. primary diagnosis of localized pc (t1-t3, n0, m0) 5. surgical or radiation treatment in the past 4-months 6. no history of non-skin cancer for the past 2 years 7. no psychiatric treatment or overt signs of severe psychopathology (e.g., psychosis, substance dependence) 8. owning a smartphone device with an android or iphone operating system (ios), which is necessary to collect the proposed ecological momentary assessment (ema) data or a valid email address. (i) willingness to wear the e4 wristband at 5 time points, over the course of 4 days (j) has a spouse/partner that is willing to participate or is willing to participate in the study alone spouses/partners: 1. female or male ≥18 years of age 2. have no history of inpatient psychiatric treatment for severe mental illness or overt signs of severe psychopathology (e.g., psychosis, substance dep., dementia) 3. willingness to be assessed and followed for 6 months 4. no life-threatening illness with a life expectancy \< 12 months 5. identifies as a spouse/partner and is willing to participate in the study. exclusion criteria: * not meeting all of the inclusion criteria

Keywords: prostate cancer survivors cognitive stress management hispanic/latino
treatment of congenital factor vii deficiency

Conditions: Congenital Bleeding Disorder; Congenital FVII Deficiency

Summary: this study is conducted globally. the aim of this study is to describe the treatment modalities and outcomes of bleeding episodes, surgery and prophylaxis in patients with factor vii (fvii) deficiency in addition to evaluate the presence (in already treated patients) and/or the appearance of inhibiting antibodies to fvii and/or therapy-related thrombosis. due to a novo nordisk commitment to the committee for medicinal products for human use (chmp), novo nordisk receives data on treatment with activated recombinant human fvii (rfviia, novoseven®) in patients with fvii deficiency from the seven treatment evaluation registry (ster, nct01269138). these patients can also have been treated with other haemostatics for systemic administration.


Eligibility criteria:
inclusion criteria: * signed informed consent by the patient or next of kin or legally acceptable representative to collect data on treatment of a given bleeding episode, surgical event or prophylactic regimen as specified in the protocol. if informed consent is provided by the next of kin or legally acceptable representative, consent must also be obtained from the patient as soon as he/she is able to do so. informed consent should preferentially be obtained before initiation of treatment or as a minimum before entry of data into the database * any patient with a fvii deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by the treating physician can be enrolled * patients with fvii deficiency without any immediate need for treatment will be entered as stand by registered patients with capture of baseline- and demographic data only. admission data is entered once an event occurs
zinc supplement before or with food in generally healthy men

Conditions: Zinc Deficiency; Dyslipidemias; Zinc Excess; Inflammation

Summary: the purpose of this study is to determine the influence of food consumption timing on the body's response to a zinc supplement

this research is a dietary intervention study designed to evaluate the effect of the food consumption timing on the absorption of zinc supplement. the main objective is to measure plasma zinc in generally healthy male subjects, who will consume zinc supplement with food or 30-min before food for 2-weeks. in addition to the primary objectives, correlations in enzyme activity with changes in fat metabolism, namely circulating triglyceride and cholesterol, will be determined. this will enable the determination of the effect of a low zn intake on various aspects of dyslipidemia.

Eligibility criteria:
inclusion criteria: * willing to stop supplementation 4 weeks prior to start of the study * has an operative understanding of english * no plans to move from the area during the study period * regularly eat breakfast exclusion criteria: * chronic or acute metabolic disease * smoker or user of nicotine products * history of alcohol abuse, or use of illicit drugs (incl marijuana) * is underweight or overweight, body mass index (bmi) \ 30 kg/m2

Keywords: zinc nutrition supplement food
effect of sedation strategy on duration mechanical ventilation in patient after cardiac surgery

Conditions: Respiratory Failure; Mechanical Ventilation Complication; Sedation Complication

Summary: there is a direct relationship between the sedative agent and the duration of ventilation.

sedation and sedative agent have direct correlation to the mechanical length. as known mechanical length could increase length of the hospital stay (lohs) and mortality rate. the right sedative agent can decrease the length go the mechanical ventilation. the goal of the research to compare 3 sedation strategies and their influence to the duration of mechanical ventilation.

Eligibility criteria:
inclusion criteria: * multi vascular lesions of the coronary arteries according to coronary angiography; * heart valve damage was confirmed by, which is subject to surgical correction (aortic stenosis of iii degree with a gradient on the aortic valve of more than 42 mmhg, aortic insufficiency iii, mitral valve stenosis ii-iii, mitral regurgitation ii-iii) * age of patients from 18-80 years; • patient consent to participate in the study; exclusion criteria: * refusal to participate; * hypersensitivity to propofol, dexmedetomidine; * prolonged mechanical ventilation in case of surgical complications (bleeding, inadequate perfusion of the myocardium); * occurred ischemic stroke; * history of the ischemic stroke; * history of the neurodegenerative diseases; * history of the mental disorders; * use of neuroleptics, antidepressants for the last 5 years; * history of the cardiac surgery in the past; * patients with chronic pulmonary disease (gold 3-4) * patients with asthma (moderate or severe), * participation in any other clinical trial; * chronic renal failure (clcr less than 50 ml / h) * acute renal failure that occurred during surgery (clcr less than 50 ml / h, or a decrease in the rate of diuresis to 0.1 ml / h in the first 4 hours after surgery and does not respond to diuretic therapy) * chronic hepatic insufficiency if there are laboratory signs of hypo coagulation without the use of anticoagulant therapy (inr\> 1.5) * if the patient has not stopped taking anticoagulants or antiplatelet agents in the preoperative period: warfarin 5 days before surgery, clopidogrel 5-7 days before surgery, xarelto / pradaxa 3 days before surgery), * history of the hematological disease; * alcohol abuse in the anamnesis (3-4 times a week). * condition after chemotherapy; * pregnancy, lactation.

Keywords: lohs, sedation, cardiac surgery, intensive care unit
high risk crack use settings and hiv in el salvador

Conditions: HIV; Sexually Transmitted Diseases

Summary: this project will first increase the accessibility and acceptability of rapid hiv testing in health clinics located in or near four low-income communities in san salvador, el salvador. the investigators will use crack users' social networks and small incentives, as recommended by the cdc, in collaboration with the salvadoran ministry of public health and social assistance (mspas) to encourage crack users to receive hiv testing. the second part of the intervention consists of training 8 peer leaders to recruit and lead a peer network intervention among 400 crack users to change norms supporting hiv protective behaviors. the intervention will include monthly meetings open to crack using and non-crack using community residents to reinforce hiv risk reduction skills, and discussion of other topics related to hiv such as illicit drug use and interpersonal violence and community-wide hiv awareness events. our hypothesis is that these two intervention features will singly, and in combination, reduce hiv risk behaviors among salvadoran crack users.


Eligibility criteria:
inclusion criteria: * 18 years or older * used crack cocaine in the last 2 weeks exclusion criteria: * not giving informed consent * under 18 years of age * considered by research staff to be unfit or unable to give informed consent * engages in continued disruptive behavior while participating in the project * not using crack or cocaine in the last month
a study evaluating the efficacy and safety of ckd-314 (nafabelltan) in hospitalized adult patients diagnosed with covid-19 pneumonia

Conditions: COVID-19

Summary: the primary objective of this study is to evaluate the efficacy of ckd-314 (nafabelltan) compared to standard of care (soc), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients diagnosed with covid-19 pneumonia


Eligibility criteria:
inclusion criteria: * men and women aged ≥18 years * hospitalized subjects who have confirmed covid-19 infection and have evidence of pneumonia: * subjects who are eligible for diagnosis/evaluation to chest x-ray or chest ct * women of childbearing potential (including women in post menopause for less than 2 years) must use a medically acceptable forms of birth control and agree to continue its use during the study * subjects (or legally authorized representative) should be able to understand and agree to comply with the clinical trial and to provide a written consent document prior to initiation of any study procedure exclusion criteria: * subjects who have a record of hiv or aids * subject has a serious chronic disease * active bleeding or ongoing clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment * pregnant or lactating females * subjects with liver cirrhosis whose child-pugh score is b or c * subjects who have liver disease abnormalities with alt or ast \> 5 times uln * estimated glomerular filtration rate (egfr) \< 30 ml/min (including patients receiving hemodialysis or hemofiltration) * qtcb or qtcf \>500ms * subjects who have clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) in medical history * subjects with rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator's opinion * subjects who are not appropriate for the study, as the investigator's opinion * subjects who have hypersensitivity to the investigational drug * subjects participated in any other clinical trial (including drugs for the treatment of covid-19) 3 months prior to screening
a study to compare abp 234 and keytruda® (pembrolizumab) in participants with advanced or metastatic non-squamous non-small cell lung cancer

Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Summary: the primary objective of this study is to compare the efficacy of abp 234 with the pembrolizumab reference product (keytruda®).


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age. 2. histologically or cytologically confirmed stage iv non-squamous non-small cell lung cancer (nsclc). 3. participant has no prior systemic treatment for advanced disease. 4. measurable disease according to recist v1.1. 5. tumor tissue from the resected site of disease must be available for biomarker analyses in order to be randomized. 6. eastern cooperative oncology group performance status score 0 or 1. 7. epidermal growth factor receptor (egfr), anaplastic lymphoma kinase (alk), and c-ros oncogene 1, receptor tyrosine kinase of the insulin receptor family (ros-1) negative 8. have a life expectancy of at least 3 months. exclusion criteria: 1. small cell lung cancer (sclc) or mixed sclc/nsclc histology or squamous cell carcinoma. 2. participant has active central nervous system metastases not previously treated. 3. participant has active or known immune-mediated disorders. 4. participant has received prior systemic cytotoxic chemotherapy, immunotherapy (including pd-1/pd-l1), anti-neoplastic biological therapy, or targeted therapy for advanced/metastatic disease. 5. known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug, or to any component of cisplatin, carboplatin, or pemetrexed.
peptide profiles of women undergoing breast biopsy

Conditions: Breast Cancer

Summary: this study is being done to learn about blood proteins. we want to see if the blood proteins in women whose biopsies show breast cancer are different from the blood proteins in women whose biopsies do not show breast cancer. the goal of this study is to develop a blood test than can help detect breast cancers when they are very small and easy to cure.

despite currently available screening techniques, only 63% of breast cancer cases are diagnosed at a localized stage, for which the 5-year survival rate exceeds 95% (1). advances in breast imaging are occurring, but further efforts to detect breast cancer at an early stage would be beneficial. recently, new technologies which use mass spectrometric analysis to characterize the overall pattern of peptide expression in the serum or plasma have been developed. preliminary studies have suggested that peptide profiles can be used to differentiate cancer patients from those without cancer for a variety of malignancies including breast cancer. if mass spectrometric analysis is able to detect differences in peptide profiles between early stage breast cancers and normal controls, this technique could be developed as a screening modality. the objective of the present study which is entitled "peptide profiles of women undergoing breast biopsy" is to determine whether the diagnosis of malignancy on breast biopsy is associated with a specific serum or plasma peptide profile which can be distinguished from the peptide profile associated with benign diagnoses on breast biopsy. to accomplish this, blood samples will be collected from 500 women undergoing breast biopsy and 100 women with metastatic disease. samples will be obtained prior to the biopsies and analyzed by mass spectrometry. residual material will be shared with investigators of the national cancer institute clinical proteomics technology assessment consortium.

Eligibility criteria:
inclusion criteria: * female * age ≥ or = to 18 cohort a: biopsy cohort: * referred by a healthcare provider for breast biopsy * no prior history of invasive breast cancer or of ductal carcinoma in situ * no prior history of other malignancies within 5 years except cervical dysplasia, squamous cell carcinoma of the skin or basal cell carcinoma of the skin cohort b: metastatic disease cohort - diagnosis of stage iv breast cancer exclusion criteria: * male * age \< 18

Keywords: breast cancer breast biopsy
effects of acupuncture in the treatment of infant colic

Conditions: Infant Colic

Summary: standardized acupuncture treatment for infant colic is a common treatment in general practice for doctors educated in medical acupuncture. the investigators plan to study whether the perceived opinion on positive results can be verified in a multi-center clinical trial. the investigators aim to measure the effect of standardized acupuncture treatment, three repeated sessions, on infant colic in a randomized singe blinded prospective multi-center study, starting september 2009. the study will be done in thirteen locations in norway by specialists in general practice trained in acupuncture. the investigators intend to include a total of 130 patients, 65 in the intervention group and 65 in the control group.


Eligibility criteria:
inclusion criteria: * infants under 3 months of age with birth weight over 2500 g and/or over 36th week of gestation. * further fulfilling wessel et al criteria for infant colic: "paroxystic uncontrollable crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying per day for more than 3 days a week for more than 3 weeks." exclusion criteria: * infants over 3 months of age with birth weight under 2500 g and/or under 36th week of gestation. * not fulfilling wessel et al criteria for infant colic: "paroxystic uncontrollable crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying pr.day for more than 3 days a week for more than 3 weeks."

Keywords: infant colic acupuncture general practice
study on anti-inflammatory effects of topical r115866 gel

Conditions: Cutaneous Inflammation

Summary: the purpose of this exploratory trial is to assess the anti-inflammatory effect(s) of topical r115866 in a model of uvb-induced inflammation and in a model of cutaneous irritation.


Eligibility criteria:
inclusion criteria: * body mass index should be between 18 and 28 kg/m2 * subjects are healthy as determined by medical history, physical examination and clinical laboratory tests carried out at screening * subjects with a phototype iii or iv (according to fitzpatrick classification) exclusion criteria: * subjects with history of or active alcohol or substance abuse problems. * known hypersensitivity to azoles, adapalene, retinoids or any other ingredient of the gels * subjects who have a laboratory value which, in the opinion of the investigator, is clinically-relevant out of the normal range * subjects with clinically relevant abnormal ecg-intervals or morphology of the ecg, qtc interval \>450 ms * use of vitamin a (\>1000 µg/day) or the use of concomitant medication, except paracetamol; all other medication must have been stopped at least 14 days before the first administration of gel) * subjects who have received an investigational product which is not a biological within the month preceding the screening visit; if the investigational product is a biological, a 3-month wash-out period is required. * use of ultraviolet light (including artificial uva and uvb as well as excessive natural sun exposure) unless stopped at visit 1 * subjects judged by the investigator to have a high probability of lack of compliance with the provisions of the protocol * subjects having any medical condition which, in the opinion of the investigator at the site, is a contraindication to enrollment
family planning knowledge, attitudes, and practices of postpartum malawian women

Conditions: Contraception

Summary: the purpose of this study is to understand the family planning needs and practices of postpartum malawian women, with a focus on long-acting reversible contraception (larc). hypotheses: 1. postpartum women who are older, who have a history of unintended pregnancy, who do not desire another child within 2 years, and who were counseled about larc during their pregnancy are more likely to have interest in using larc. 2. postpartum women who are older are more likely to be aware of larc methods. 3. hiv+ postpartum malawian women will have similar knowledge about larc as postpartum malawian women who are hiv-.

this study is a prospective cohort study of 630 postpartum malawian women. since our focus is on hiv+ women, hiv+ participants will be recruited in a 1:2 ratio, with a total of 210 hiv+ women and 420 hiv- women. we will recruit in the postpartum ward of bwaila maternity hospital in lilongwe, malawi. participants will complete a baseline survey about demographics, reproductive health history, and family planning knowledge, attitudes, and practices. at 3, 6, and 12 months postpartum, we will complete follow-up phone calls to determine what family planning methods they are using and if they encountered any barriers to receiving larc if they had been interested in using them.

Eligibility criteria:
inclusion criteria: 1. admission to the postpartum ward at bwaila maternity hospital 2. live birth ≥28 weeks gestational age within past 4 weeks 3. fluent in english or chichewa 4. age 18-45 years 5. access to a working phone number 6. willingness to be contacted by phone for up to one year postpartum exclusion criteria: 1. history of female sterilization via tubal ligation or hysterectomy 2. prisoner 3. history of mental disability 4. serious illness that would prevent participation in the opinion of the principal investigator